Complete the form to get the full interpretation guide 
 

The VENTANA ALK (D5F3) CDx Assay is FDA approved to run on your BenchMark IHC/ISH staining instrument as a stand-alone assay to identify ALK+ NSCLC patients eligible for XALKORI (crizotinib), ZYKADIA (ceritinib) and ALECENSA't (alectinib). Another option is to send the assay to one of our testing centers. 

Empower your lab to provide timely results that lead to confident decisions with: 

• Easy binary scoring 
• Fully automated, 4 1/2-hour turnaround time 
• Brightfield vs. fluorescent staining

We value your privacy.

VENTANA ALK (D5F3) CDx Assay: Indentifying ALK+ NSCLC Patients for Targeted Treatment
 

Learn more about NSCLC and how to identify patiences who may be appropriate for ALK+ targeted treatment.

Roche Diagnostics University
 

Find online training courses for the VENTANA ALK (D5F3) CDx Assay. Topics include indentifying ALK+ NSCLC patients for targeted treatment.